Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Lung Cancer Specimen Reference Set A (Full) Application: Hirschowitz - University of Kentucky (2009)

Lung Cancer Specimen Reference Set A (Full) Application: Hirschowitz - University of Kentucky (2009)

279
Case/control
Proteomics
Lung and Upper Aerodigestive Cancers Research Group
1

We are continuing validation with two advanced objectives: 1) To evaluate assay performance for established lung cancer diagnosed in a clinical population 2) to confirm results that indicate this marker set may detect cancer and predict the onset of NSCLC prior to radiographic detection in a screened population.

Aim 1. To pre-validate assay performance in a high-risk clinical population from an alternate demographic. We intend to validate the predictive accuracy of our markers for clinically diagnosed lung cancer, identify the limits of the assay in individuals with benign lung disease, and determine marker specificity for lung vs. other cancers. Pre-validation will define performance in samples from an alternate demographic and generate classifiers with which to construct optimalperformance criteria that can be applied to class prediction for subsequent blinded analysis of a larger EDRN clinical reference set.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.